BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35689385)

  • 21. Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values.
    Galaski J; Schulz L; Krause J; Lohse AW
    Z Gastroenterol; 2018 Jan; 56(1):36-42. PubMed ID: 29316576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
    Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
    Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
    Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
    Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
    Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.
    Ratchatasettakul K; Rattanasiri S; Promson K; Sringam P; Sobhonslidsuk A
    BMC Gastroenterol; 2017 Apr; 17(1):50. PubMed ID: 28407734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
    Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
    Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: A biopsy-controlled study.
    Darweesh SK; Omar H; Medhat E; Abd-Al Aziz RA; Ayman H; Saad Y; Yosry A
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1010-1016. PubMed ID: 30807444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements.
    Mikolasevic I; Poropat G; Filipec Kanizaj T; Skenderevic N; Zelic M; Matasin M; Vranic L; Kresovic A; Hauser G
    Can J Gastroenterol Hepatol; 2021; 2021():6670065. PubMed ID: 33688490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.
    Kuroda H; Fujiwara Y; Abe T; Nagasawa T; Oguri T; Noguchi S; Kamiyama N; Takikawa Y
    PLoS One; 2021; 16(4):e0249493. PubMed ID: 33826669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
    Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
    Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    Cai YJ; Dong JJ; Wang XD; Huang SS; Chen RC; Chen Y; Wang YQ; Song M; Chen YP; Li Z; Zhou MT; Shi KQ
    J Viral Hepat; 2017 Nov; 24(11):1005-1015. PubMed ID: 28419755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.
    Hsu PK; Wu LS; Su WW; Su PY; Chen YY; Hsu YC; Yen HH; Wu CL
    PLoS One; 2021; 16(10):e0254892. PubMed ID: 34653177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.